BioMarin Pharmaceutical/ US09061G1013 /
| 2024-04-15 9:59:57 PM | Chg. -0.72 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 91.51USD | -0.78% | 92,347 Turnover: 8.51 mill. |
-Bid Size: - | -Ask Size: - | 17.27 bill.USD | - | 102.82 |
Assets
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 1,010.8680 | 1,032.4710 | 1,035.4610 | 1,073.3660 | 1,066.1330 | ||||||
| Intangible Assets | 456.5800 | 417.2710 | 388.6520 | 338.5690 | 294.7010 | ||||||
| Long-Term Investments | 411.9780 | 285.4730 | 507.7930 | 333.8350 | 611.1350 | ||||||
| Fixed Assets | 2,747.8960 | 3,505.8010 | 3,728.9400 | 3,623.6170 | 3,885.5150 | ||||||
| Inventories | 680.2750 | 698.5480 | 776.6690 | 894.0830 | 1,107.1830 | ||||||
| Accounts Receivable | 377.4040 | 448.3510 | 373.3990 | 461.3160 | 633.7040 | ||||||
| Cash and Cash Equivalents | 437.4460 | 649.1580 | 587.2760 | 724.5310 | 755.1270 | ||||||
| Current Assets | 1,942.1430 | 2,342.2190 | 2,274.3850 | 2,751.4570 | 2,956.0880 | ||||||
| Total Assets | 4,690.0390 | 5,848.0200 | 6,003.3250 | 6,375.0740 | 6,841.6030 | ||||||
Liabilities
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | - | - | - | - | - | ||||||
| Long-term debt | 486.2380 | 1,075.1450 | 1,079.0770 | 1,083.0190 | 593.0950 | ||||||
| Liabilities to Banks | 0.0000 | 0.0000 | 0.0000 | - | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 1,567.6580 | 1,742.0180 | 1,732.5850 | 1,771.9180 | 1,890.0540 | ||||||
| Share Capital | .1800 | .1820 | .1840 | .1860 | .1890 | ||||||
| Total Equity | 3,122.3810 | 4,106.0020 | 4,270.7400 | 4,603.1560 | 4,951.5490 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 4,690.0390 | 5,848.0200 | 6,003.3250 | 6,375.0740 | 6,841.6030 | ||||||
Income Statement
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1,704.0480 | 1,860.4550 | 1,846.2750 | 2,096.0390 | 2,419.2260 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | -100.4570 | -36.7650 | -82.3410 | 149.5620 | 158.0970 | ||||||
| Interest Income | -.7120 | -12.6990 | -4.8550 | 2.0640 | 41.0040 | ||||||
| Income Before Taxes | -94.8110 | -42.3220 | -75.3500 | 149.5760 | 188.5630 | ||||||
| Income Taxes | -70.9630 | -901.4220 | -11.2700 | 8.0150 | 20.9180 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | -23.8480 | 859.1000 | -64.0800 | 141.5610 | 167.6450 | ||||||
Per Share
Cash Flow
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 48.2620 | 85.3650 | 304.5360 | 175.9020 | 159.2590 | ||||||
| Cash Flow from Investing Activities | -31.0260 | -53.6210 | -366.3130 | -20.0290 | -111.2440 | ||||||
| Cash Flow from Financing | -74.6740 | 181.1180 | -.0480 | -18.6500 | -18.7270 | ||||||
| Decrease / Increase in Cash | -56.5360 | 211.7120 | -61.8820 | 137.2550 | 30.5960 | ||||||
| Employees | 3,001 | 3,059 | 3,045 | - | - | ||||||
